Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, November 7, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mani Foroohar Maintained (ALVR) at Buy with Increased Target to $25 on, Nov 7th, 2022
Mani Foroohar of SVB Leerink, Maintained "AlloVir, Inc." (ALVR) at Buy with Increased Target from $24 to $25 on, Nov 7th, 2022.
Mani has made no other calls on ALVR in the last 4 months.
There is 1 other peer that has a rating on ALVR. Out of the 1 peers that are also analyzing ALVR, 0 agree with Mani's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mani
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $27 on, Friday, September 9th, 2022
